• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Revance Therapeutics (NQ: RVNC )

    5.360 -0.030 (-0.56%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,030,253
    Open 5.450
    Bid (Size) 5.350 (109)
    Ask (Size) 5.360 (38)
    Prev. Close 5.390
    Today's Range 5.300 - 5.510
    52wk Range 2.300 - 12.59
    Shares Outstanding 71,829,718
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
    From Kahn Swick & Foti, LLC
    Via Business Wire

    Performance

    YTD
    -42.43%
    -42.43%
    1 Month
    -18.54%
    -18.54%
    3 Month
    +107.75%
    +107.75%
    6 Month
    +8.94%
    +8.94%
    1 Year
    -55.67%
    -55.67%

    More News

    Read More
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
    Via Benzinga
    Gold Gains Over 1%; Starbucks Shares Move Higher
    Via Benzinga
    Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?
    Via InvestorPlace
    Crude Oil Surges 2%; B. Riley Financial Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    KE Holdings, KeyCorp, Revance Therapeutics, Starbucks And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
    From Revance Therapeutics, Inc.
    Via Business Wire
    Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
    From Revance Therapeutics, Inc.
    Via Business Wire
    AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
    Via The Motley Fool
    Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
    Via InvestorPlace
    Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Revance Therapeutics, Inc.
    Via Business Wire
    Revance to Participate in Upcoming Investor Conferences
    From Revance Therapeutics, Inc.
    Via Business Wire
    The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
    Via InvestorPlace
    3 Underappreciated Stocks That Could 10x in 10 Years
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
    Via Benzinga
    RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
    From Revance Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.